Bod Science Limited Quarterly Overview September 2025

Bod Science Limited (ASX: BOD), a company specialising in the distribution of cannabis-based products, announced a net operating cash outflow of AU$576,000 for the quarter ending 30 September 2025, while continuing operations under a Deed of Company Arrangement (DOCA) with Biortica Agrimed Limited. Customer receipts rose to AU$540 thousand, up 39% from the previous quarter, reflecting stronger sales volumes and the introduction of new SKUs. Additional funding of AU$496 thousand from Biortica supported operational costs, while payments of AU$35 thousand were made to directors. The company’s outflows were influenced by AU$1.06 million in administrative and legal expenses accrued since entering administration.

Operationally, Bod continues trading under the DOCA, with Biortica providing financial support as part of a planned backdoor listing. The company anticipates shareholder approval for the transaction following an extraordinary general meeting expected in late November 2025. Upon completion, Bod aims to satisfy ASX re-compliance requirements and advance integration with Biortica’s operations.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com